A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept vs Placebo in Patients With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy: The ELRISE MF Study Design (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-973; Location: LEVEL 3, HALL B3; "Other secondary endpoints include spleen volume reduction, platelet response, and changes from baseline in PROMIS Short Form v1.0-Fatigue 7a T-score and MFSAF v4.0 7-item Total Symptom Score at week 36. ECOG: Eastern Cooperative Oncology Group, GDF: growth differentiation factors, JAK: Janus kinase, IgG1: immunoglobulin G1, MF: myelofibrosis, MFSAF: MF Symptom Assessment Form, NCT: national clinical trial, PROMIS: patient-reported outcomes measurement information system, PS: performance status scale, RBC: red blood cell, TGF-β: transforming growth factor-β, TD: transfusion-dependence, TI: transfusion-independence."
Clinical • P3 data • Myelofibrosis • Oncology • TGFB1
|
|
Prithviraj Bose MD 1; Haifa Kathrin Al-Ali MD 2; Lina Benajiba MD PhD 3; Francesco Passamonti MD 4; Francesca Palandri MD PhD 5; María Laura Fox MD 6; Andrew T Kuykendall MD 7; John O Mascarenhas MD 8; Aaron T Gerds MD 9; David M Ross MD,PhD,FRACP,FRACPA 10; Katsuto Takenaka MD PhD 11; Katsuhiro Togami MD PhD 12; Leopold Sellner MD PhD 12; Amy Sexauer MD PhD 12; Rizvan Bush MS 12; Claire Harrison MD,FRCP,FRCPath 13
|